The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a positive development for the biotech sector, European regulators unexpectedly recommended approval of Acadia Pharma's Rett syndrome drug Daybu, causing the company's stock to rise on Friday. The recommendation marks a surprising reversal from the European Medicines Agency (EMA), which had previously rejected similar treatments.
The EMA's recommendation comes after Acadia had faced a setback in 2024 when the agency initially declined the drug. Daybu could become the first approved treatment for Rett syndrome in Europe, a rare neurological disorder primarily affecting girls. Per market data, the stock rose over 7% in recent trading.
Sign in to access this content
Sign InAt the close of June 26, ACAD shares traded around $27.50, posting strong daily gains. While no immediately impactful economic events appear on the calendar, investors are awaiting the EMA's final decision in the coming months, which could open access to a market valued at over $1 billion annually.